Reverse Merger vs IPO: Faster Listing Without Emptying Your Cap Table

You are choosing between an IPO and a reverse merger to get public. The trap is the ticker: it looks like the win, but the shell, the private placement, and the control split are the price. In one quarter, biotech reverse mergers reached 17 completed or pending deals, up 1,600% from a single deal in the prior quarter. Leerink Partners' 2026-to-date tally included 20 biotech IPOs and 19 reverse mergers.

The public quote is a milestone, not the finish line

A public quote helps when a board, lender, or customer asks for one. The deal also brings the shell's history, the financing that must close, and a cap table that has already been negotiated. Speed matters when you need public status to raise capital, hire, or buy. Costs show up after the listing, in the placement terms and the control math.

A reverse merger passes only if it survives a five-line scorecard

Put the scorecard on a whiteboard, then write the answers into the term sheet. Each line must be answerable before you sign, and each line must change the price if the answer is bad.

• Timeline: reverse mergers may be finished in 30 to 90 days, while IPO preparation, regulatory review, and roadshows can consume 6 to 12 months. A typical reverse merger requires four to six months before closing. Use the shorter window as the best case and the longer window as the planning number, then test whether the company can fund the gap between signing and closing.
• Shell history: fraud associations with reverse mergers were common in the early 2010s, particularly around China-based shell companies. Check who owned the shell, what it filed, what it owed, and who can still sue it. Ask whether its past can surface in early filings, not just whether it looks clean today.
• Financing size: Obsidian disclosed a $350 million private placement financing ahead of the merger's closing. When your plan depends on a raise, the placement is the deal. Ask who buys the shares, at what price, with what limits on selling, and with what rights to register the shares for sale. Divide the placement size by the total value of the company after the deal to see how much of the new company the raise owns. If the shell's investors get a cheaper entry than your existing cap table, dilution starts before trading begins.
• Post-deal control: private-company shareholders typically end up with 80% to 95% control after the reverse merger agreement is signed. Multiply your pre-deal stake by that range, then stress-test voting agreements, board seats, payment preferences, and shell-investor rights. The range sounds protective, but effective control can change before the company reports results.
• Legacy-liability exposure: the shell's past can follow you into the first public filing. Ask what debts, disputes, or filings remain, and who can still claim against the company. You want to know what protections the shell owners will give you, not just what the shell says it has resolved.

Choose the route that leaves equity, cash, and governance

An IPO raises money through a public offering, but it depends on market conditions. A reverse merger can include a private placement to fund the post-merger company. The IPO price comes from that public offering. The reverse-merger price forms privately, where the shell already has rights.

For a founder who needs to go public now, a reverse merger can be a credible path if the company has a clean shell target, a committed private placement, and a board that can survive the closing process. The control math should still leave you in charge after the placement, the voting agreements, and the board seats are counted. Without those items, the speed benefit shrinks quickly.